Cathie Wood's ARK Bets Bigger On This Biotech Play, Slashes Stake In This Space Stock
ARK Investment Management bought shares worth more than $3.5 million of Intellia Therapeutics and sold shares of Rocket Lab worth more than $4 million on Monday.
Stocktwits
More News
CMPS On Track For Best Week Ever On FDA Push For Psychedelics
Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.
Stocktwits
Tempus AI Stock Near 1-Year Low: Cathie Wood’s ARK Buys More While Offloading Nvidia, Meta, Other Tech Plays
Tempus AI was the only stock purchased by ARK Innovation ETF (ARKK) in the latest session, signaling targeted conviction.
Stocktwits
Why Is CRSP Stock Falling Pre-Market Today?
The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.
Stocktwits
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.
Stocktwits
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
Stocktwits
TWST Shares Rise 8% — What’s Driving The Rally?
Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates.
Stocktwits
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.
Stocktwits
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise
William Blair welcomed the company’s update on its alignment with the U.S. FDA, saying it gives clear visibility into the data needed for regulatory filings.
Stocktwits
Biotech ETFs Bounce Back in 2025: Here's Why
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.